Compare JD.Com Inc (JD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs Sana Biotechnology Inc — how do they compare? JD.Com Inc trades at $31.62 (market cap $44.04B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: JD.Com Inc is far larger — about 39× Sana Biotechnology Inc's market cap, and JD.Com Inc pays a 3.13% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| JD | SANA | |
|---|---|---|
Market Cap | $44.04B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $5.92 |
52-Week Low | $25.19 | $2.68 |
Enterprise Value | $30.10B | $1.05B |
Dividend Yield | 3.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $31.46, down 6.01% over 24 hours, with technical indicators showing bullish momentum despite recent pressure. The company reported strong Q1 2026 earnings of $0.74 EPS, beating expectations by 30%, while revenue grew to $1.31 trillion in 2025. Analysts maintain a bullish consensus with 32 buy ratings and a $38.00 price target, representing 21% upside potential. Recent news highlights JD's upcoming Q2 earnings report on August 13, 2026, with expectations of 618 promotion benefits.
JD presents compelling value with a P/S ratio of 0.24 and consistent earnings beats, though net margins remain thin at 1.05%. Regulatory scrutiny of the Ceconomy acquisition and competitive pressures pose risks, but institutional accumulation and bullish technicals support further upside. The stock's current level near key support at $31 offers an attractive entry point ahead of Q2 results.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
